Appraisal of Current Guidelines Regarding The Management Of Breast Cancer Using the Appraisal Of Guidelines Research and Evaluation (AGREE) Instrument: A Critical Review
DOI:
https://doi.org/10.48111/2021.03.03Keywords:
breast cancer, management, AGREE II Instrument, Clinical practice guidelines, guidelines, consensus, quality of guidelinesAbstract
With rapid advancements in breast oncology, there is a growing need for high-quality, systematically developed clinical practice guidelines (CPGs) and consensus statements (CSs). This study aims to assess the quality of the current clinical practice guidelines and consensus statements related to the management of breast cancer employing the Appraisal of Guidelines Research and Evaluation (AGREE) II tool.
METHODS A systematic literature search of bibliographic databases (PubMed and Google Scholar) and 20 professional society websites was conducted from January 2019 onwards. Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument was used to evaluate the methodological quality of the included CPGs and CSs.
RESULTS The analysis of the AGREE II overall assessment of CPGs and CSs revealed a wide overall score range. The median overall score across the guidelines was 61%. The highest overall score was obtained by the American Society of Clinical Oncology (ASCO) guidelines, with scores ranging from 80-91%, followed by 5th ESO-ESMO ABC5 (77%), 4th ESO-ESMO BCY4 (76%) and V.4 NCCN (74%). Overall, CSs had a lower quality in the majority of the domains as compared to CPGs.
CONCLUSIONS The authors believe that the guidelines related to breast cancer management have a wide room for improvement. There is a growing need for CPGs/CSs that employ uniformly endorsed standards. Guideline development standards are the current state-of-the-art, and guideline developers must direct their efforts towards acknowledging and incorporating them into guidelines.
References
Organization WH. Breast Cancer. Published 2021. https://www.who.int/news-room/fact-sheets/detail/breast-cancer
Lei X, Liu F, Luo S, et al. Evaluation of guidelines regarding surgical treatment of breast cancer using the AGREE Instrument: a systematic review. BMJ open. 2017;7(11):e014883. doi:10.1136/bmjopen-2016-014883
Kumar Tyagi N, Dhesy-Thind S. Clinical practice guidelines in breast cancer. Current Oncology. 2018;25:S151-S160. doi:10.3747/CO.25.3729
Maes-Carballo M, Mignini L, Martín-Díaz M, Bueno-Cavanillas A, Khan KS. Quality and reporting of clinical guidelines for breast cancer treatment: A systematic review. Breast (Edinburgh, Scotland). 2020;53:201-211. doi:10.1016/j.breast.2020.07.011
Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J H, SE, Littlejohns P, Makarski J ZL. AGREE Next Steps Consortium. AGREE II: Advancing guideline development, reporting and evaluation in healthcare. CMAJ. Published online 2010:182:E839-842. https://www.agreetrust.org/wp-content/uploads/2017/12/AGREE-II-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf
D M, A L, J T, DG A. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine. 2009;6(7). doi:10.1371/JOURNAL.PMED.1000097
Vernooij RWM, Sanabria AJ, Solà I, Alonso-Coello P, Martínez García L. Guidance for updating clinical practice guidelines: a systematic review of methodological handbooks. Implementation science : IS. 2014;9:3. doi:10.1186/1748-5908-9-3
Hoffmann-Eßer W, Siering U, Neugebauer EAM, Lampert U, Eikermann M. Systematic review of current guideline appraisals performed with the Appraisal of Guidelines for Research & Evaluation II instrument—a third of AGREE II users apply a cut-off for guideline quality. Journal of Clinical Epidemiology. 2018;95:120-127. doi:10.1016/J.JCLINEPI.2017.12.009
Cancer Australia, Surry Hills NSW. Guidance for the management of early breast cancer: Recommendations and practice points. Published online 2020. https://www.canceraustralia.gov.au/publications-and-resources/cancer-australia-publications/guidance-management-early-breast-cancer-recommendations-and-practice-points
Ditsch N, Kolberg-Liedtke C, Friedrich M, et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast care (Basel, Switzerland). 2021;16(3):214-227. doi:10.1159/000516419
Thill M, Jackisch C, Janni W, et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast care (Basel, Switzerland). 2019;14(4):247-255. doi:10.1159/000500999
Unit GR. Systemic Therapy for Early Breast Cancer - Quick Reference Guide -. 2021;(April). https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-systemic-therapy-early-breast.pdf
Hassett MJ, Somerfield MR, Baker ER, et al. Management of Male Breast Cancer: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020;38(16):1849-1863. doi:10.1200/JCO.19.03120
Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39(13):1485-1505. doi:10.1200/JCO.20.03399
Visvanathan K, Fabian CJ, Bantug E, et al. Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019;37(33):3152-3165. doi:10.1200/JCO.19.01472
Denduluri N, Somerfield MR, Chavez-MacGregor M, et al. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39(6):685-693. doi:10.1200/JCO.20.02510
Brackstone M, Baldassarre FG, Perera FE, et al. Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39(27):3056-3082. doi:10.1200/JCO.21.00934
Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Published online July 29, 2021:JCO2101392. doi:10.1200/JCO.21.01392
Tung NM, Zakalik D, Somerfield MR, Hereditary Breast Cancer Guideline Expert Panel. Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39(26):2959-2961. doi:10.1200/JCO.21.01532
Moy B, Rumble RB, Come SE, et al. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Published online July 29, 2021:JCO2101374. doi:10.1200/JCO.21.01374
Manoj Gowda S, Kabeer KK, Jafferbhoy S, et al. Breast Cancer Management Guidelines During COVID-19 Pandemic. The Indian journal of surgery. Published online July 2, 2020:1-8. doi:10.1007/s12262-020-02466-7
Jiao D-C, Zhu J-J, Qin L, et al. Clinical practice guidelines for modified radical mastectomy of breast cancer: Chinese Society of Breast Surgery (CSBrs) practice guidelines 2021. Chinese medical journal. 2021;134(8):895-897. doi:10.1097/CM9.0000000000001412
Liu M, Wang C-B, Xie F, Peng Y, Wang S, Chinese Society of Breast Surgery. Clinical practice guidelines for diagnosis and treatment of invasive breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021. Chinese medical journal. 2021;134(9):1009-1013. doi:10.1097/CM9.0000000000001498
Ma L, Ge Z-C, Xin L, et al. Clinical practice guidelines for breast cancer implantable intravenous infusion ports: Chinese Society of Breast Surgery practice guidelines 2021. Chinese medical journal. 2021;134(16):1894-1896. doi:10.1097/CM9.0000000000001522
Chen K, Liu J-Q, Wu W, et al. Clinical practice guideline for breast-conserving surgery in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021. Chinese medical journal. Published online June 16, 2021. doi:10.1097/CM9.0000000000001518
Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of oncology : official journal of the European Society for Medical Oncology. 2019;30(8):1194-1220. doi:10.1093/annonc/mdz173
Martin M, Guerrero-Zotano A, Montero Á, et al. GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain. The oncologist. 2020;25(9):e1339-e1345. doi:10.1634/theoncologist.2020-0363
Daraï E, Mathelin C, Gligorov J. Breast Cancer Management during the COVID 19 Pandemic: French Guidelines. European journal of breast health. 2020;16(3):160-161. doi:10.5152/ejbh.2020.200420
Inokuchi M, Kutomi G, Kijima Y, et al. The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition. Breast cancer (Tokyo, Japan). 2020;27(1):4-8. doi:10.1007/s12282-019-01030-w
Shimoi T, Nagai SE, Yoshinami T, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Breast cancer (Tokyo, Japan). 2020;27(3):322-331. doi:10.1007/s12282-020-01085-0
Iwata H, Saji S, Ikeda M, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient. Breast cancer (Tokyo, Japan). 2020;27(1):1-3. doi:10.1007/s12282-019-01021-x
National Health Commission Of The People’s Republic Of China. Chinese guidelines for diagnosis and treatment of breast cancer 2018 (English version). Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. 2019;31(2):259-277. doi:10.21147/j.issn.1000-9604.2019.02.02
Mcneill C. Breast Cancer Clinical Guidelines Title: NCA Breast Cancer Clinical Guidelines Authors: Breast EAG members Circulation List: Breast EAG. 2020;(May 2016):1-117. https://www.northerncanceralliance.nhs.uk/wp-content/uploads/2019/02/NCA-Breast-Cancer-Guidelines-v2-.10.pdf
Gradishar WJ, Moran MS, Abraham J, et al. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. Journal of the National Comprehensive Cancer Network : JNCCN. 2021;19(5):484-493. doi:10.6004/jnccn.2021.0023
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer | Guidance | NICE 1 Recommendations |. 2021;(March). https://www.nice.org.uk/guidance/ta593/chapter/1-Recommendations
NICE. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer 1 Recommendations. 2018;(June).
NICE. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies. 2021;(May). www.nice.org.uk/guidance/ta704
NICE TA579. Abemaciclib with fulvestrant for treating hormone HER2-negative advanced breast cancer after endocrine therapy. 2020;(May 2019).
National institute for Health and Care Excellence N. Pertuzumab for adjuvant treatment of e early stage breast cancer. 2019;(March 2019):16.
National Institute for Health and Care Excellence (NICE). Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. Technology appraisal guidance [TA639]. 2020;(July):1-19.
Khan S, Richardson J. Palbociclib with fulvestrant for treating hormone breast cancer. 2020;(January):20.
National Institute for Health and Care Excellence (NICE). Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab. Technology appraisal guidance [TA612]. 2019;(November 2019). https://www.nice.org.uk/guidance/TA612
National Institute for Health and Care Excellence. Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. Technology appraisal guidance [TA563]. 2019;(February 2019). https://www.nice.org.uk/guidance/ta563
Dowsett M, Ellis MJ, Dixon JM, et al. Evidence-based guidelines for managing patients with primary ER+ HER2? breast cancer deferred from surgery due to the COVID-19 pandemic. npj Breast Cancer. 2020;6(1):21. doi:10.1038/s41523-020-0168-9
Simpson LK, Chin SN, East J, et al. Guidelines on management of the patient with breast cancer. West Indian Medical Journal. 2019;68:55-72. doi:10.7727/wimj.2018.198
American Society of Breast Surgeons T. Consensus Guideline on the Management of the Axilla in Patients With Invasive/In-Situ Breast Cancer Purpose. Published online 2014:1-12. https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-the-Management-of-the-Axilla.pdf?v2
Chacón López-Muñiz JI, de la Cruz Merino L, Gavilá Gregori J, et al. SEOM clinical guidelines in advanced and recurrent breast cancer (2018). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2019;21(1):31-45. doi:10.1007/s12094-018-02010-w
Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of oncology : official journal of the European Society for Medical Oncology. 2020;31(12):1623-1649. doi:10.1016/j.annonc.2020.09.010
Xu B, Hu X, Feng J, et al. Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). Cancer. 2020;126 Suppl:3867-3882. doi:10.1002/cncr.32832
Paluch-Shimon S, Cardoso F, Partridge AH, et al. ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). Annals of oncology : official journal of the European Society for Medical Oncology. 2020;31(6):674-696. doi:10.1016/j.annonc.2020.03.284
Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of oncology : official journal of the European Society for Medical Oncology. 2021;32(10):1216-1235. doi:10.1016/j.annonc.2021.06.023
Nava MB, Benson JR, Audretsch W, et al. International multidisciplinary expert panel consensus on breast reconstruction and radiotherapy. The British journal of surgery. 2019;106(10):1327-1340. doi:10.1002/bjs.11256
Bešlija S, Gojkovi? Z, Ceri? T, et al. 2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina. Bosnian journal of basic medical sciences. 2021;21(2):120-135. doi:10.17305/bjbms.2020.4846
Published
Issue
Section
License
Copyright (c) 2021 Hadia Baig, Talat Waseem
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
